Kindred Biosciences (KIN) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Kindred Healthcare (KND) Reports KIND-012 Met Primary Endpoint in Pilot Field Study of Pyrexia in Horses
March 16, 2015 4:04 PM EDTKindred Biosciences (NASDAQ: KIN) announced positive results from its pilot field study of KIND-012 for the control of pyrexia (fever) in horses.
This study, which is the equivalent of a Phase 2 study, was a randomized, blinded, placebo-controlled, crossover study that enrolled 31 adult horses. The... More
